Clinical Trial Update: Study to Determine Optimum Intravenous Starting Dose of MIRCERA for Treatment of Pediatric Participants With Anemia and Chronic Kidney Disease on Hemodialysis [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating the optimum intravenous starting dose of MIRCERA for treatment of pediatric anemia due to chronic kidney disease in children on …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease in Pediatric Patients
• Renal Anemia

Drugs mentioned

• MIRCERA (METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Renal Anemia | Phase 2 | Status: COMPLETED | Results posted: 2017-09-08